CK Life Sciences forms new subsidiary to advance its therapeutic cancer vaccine

CK Life Sciences (0775) said it has established a new subsidiary called Sequencio Therapeutics Company to advance its therapeutic cancer vaccine portfolio.

The establishment has consolidated the company’s therapeutic cancer vaccine research and development portfolio under a dedicated organization, the company said in a filing on Tuesday. 

Sequencio is focused on the development of therapeutic cancer vaccines designed to train a patient’s own immune system to achieve durable, long-term remission with a favourable safety profile, addressing key limitations of current standard-of-care therapies, it said.